Therapeutic use of specific ligand in MSRV associated diseases
The present invention deals with a ligand comprising each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1(SEQ ID No. 1), from 0 to 2 in CDR2(SEQ ID No. 2), from 0 to 2 in CDR3(SEQ ID No. 3), from 0 to 1 in CDR4(SEQ ID No. 4), from 0 to 4 in CDR5(SEQ ID No. 5), from 0 to 2 in CDR6(SEQ ID No. 6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.
1. A ligand comprising each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6.
2. A ligand comprising:
a light chain variable region (VL) comprising the amino acid sequences set forth in SEQ ID No. 1, SEQ ID No. 2 and SEQ ID No. 3 or any sequence having at least 80% of identity with said sequences, and
a heavy chain variable region (VH) comprising the amino acid sequences set forth in SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having at least 80% of identity with said sequences.
3. A ligand comprising:
a light chain variable region (VL) having the amino acid sequence set forth in SEQ ID No. 7, or any sequence having at least 75% of identity with said sequence; and
a heavy chain variable region (VH) having the amino acid sequence set forth in SEQ ID No. 8 or any sequence having at least 75% of identity with said sequence.
4. An scFV fragment comprising the ligand of claim 1 .
5. A Fab fragment comprising the ligand of claim 1 .
6. An antibody comprising the ligand of claim 1 .
7. The antibody of claim 6 wherein it is a chimeric, engineered or humanized antibody.
8. The antibody of claim 6 which is an IgG.
9. The antibody of claim 8 which is a human IgG1 or IgG4.
10. A pharmaceutical composition comprising the ligand of claim 1 as an active ingredient.
11. An immunoassay kit for the detection of an anti-ligand in a biological sample, said kit comprising a ligand according to claim 1 , and reagents for the detection of specific binding of the anti-ligand to the ligand.
12. The immunoassay kit according to claim 11 further comprising a ligand that specifically binds to GAG antigen.
13. An scFV fragment comprising the ligand of claim 2 .
14. A Fab fragment comprising the ligand of claim 2 .
15. An antibody comprising the ligand of claim 2 .
16. An scFV fragment comprising the ligand of claim 3 .
17. A Fab fragment comprising the ligand of claim 3 .
18. An antibody comprising the ligand of claim 3 .
19. The ligand of claim 2 , wherein:
the light chain variable region (VL) comprises amino acid sequences having at least 90% sequence identity with the amino acid sequences set forth in SEQ ID No. 1, SEQ ID No. 2 and SEQ ID No. 3, respectively; and
the heavy chain variable region (VH) comprises amino acid sequences having at least 90% sequence identity with the amino acid sequences set forth in SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6, respectively.
20. The ligand of claim 3 , wherein:
the light chain variable region (VL) has an amino acid sequence having at least 90% sequence identity with the amino acid sequence set forth in SEQ ID No. 7; and
the heavy chain variable region (VH) has an amino acid sequence having at least 90% sequence identity with the amino acid sequence set forth in SEQ ID No. 8.